We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+43.59%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$149M
Cap. Flow
-$99M
Cap. Flow %
-9.49%
Top 10 Hldgs %
81.6%
Holding
33
New
2
Increased
4
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$56.8M
2
RVMD icon
Revolution Medicines
RVMD
+$26.7M
3
ANNX icon
Annexon
ANNX
+$5.84M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.14M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$774K

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$71.2M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.9M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$22.2M
4
PHVS icon
Pharvaris
PHVS
+$17.8M
5
NTRA icon
Natera
NTRA
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 98.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$263M 25.23%
3,577,267
– –
NAMS icon
2
NewAmsterdam Pharma
NAMS
$3.34B
$117M 11.21%
10,473,913
– –
PHVS icon
3
Pharvaris
PHVS
$2.41B
$110M 10.5%
3,904,319
-880,355
-18% -$17.8M
IRON icon
4
Disc Medicine
IRON
$3.01B
$77M 7.38%
1,332,545
– –
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$11.8B
$75.1M 7.2%
+324,619
New +$56.8M
SVRA icon
6
Savara
SVRA
$1.19B
$66.9M 6.41%
14,232,751
– –
CABA icon
7
Cabaletta Bio
CABA
$453M
$45.4M 4.35%
2,000,000
– –
ANNX icon
8
Annexon
ANNX
$898M
$36.6M 3.51%
8,061,719
+2,359,793
+41% +$5.84M
RVMD icon
9
Revolution Medicines
RVMD
$44.4B
$31.9M 3.06%
+1,112,396
New +$26.7M
TNGX icon
10
Tango Therapeutics
TNGX
$4.51B
$28.6M 2.75%
2,892,663
– –
NTRA icon
11
Natera
NTRA
$46.5B
$25.1M 2.4%
400,197
-300,000
-43% -$15M
SYRS
12
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$21.4M 2.05%
2,749,808
+625,114
+29% +$2.14M
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$20.1M 1.93%
346,547
– –
SLDB icon
14
Solid Biosciences
SLDB
$908M
$19.2M 1.84%
3,130,422
– –
NRIX icon
15
Nurix Therapeutics
NRIX
$2.65B
$18.8M 1.8%
1,822,883
– –
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$15.6M 1.49%
1,431,058
– –
XFOR icon
17
X4 Pharmaceuticals
XFOR
$454M
$14.2M 1.36%
563,859
+31,839
+6% +$774K
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.21B
$9.69M 0.93%
3,000,000
– –
CCCC icon
19
C4 Therapeutics
CCCC
$409M
$9.28M 0.89%
1,642,210
– –
IVVD icon
20
Invivyd
IVVD
$204M
$7.63M 0.73%
1,937,207
– –
AVIR icon
21
Atea Pharmaceuticals
AVIR
$415M
$7.58M 0.73%
2,485,638
– –
RPID icon
22
Rapid Micro Biosystems
RPID
$81.7M
$6.24M 0.6%
8,434,560
– –
NAUT icon
23
Nautilus Biotechnolgy
NAUT
$121M
$5.98M 0.57%
2,000,000
– –
TSVT
24
DELISTED
2seventy bio
TSVT
$5.69M 0.55%
1,331,801
-77,100
-5% -$237K
ACRS icon
25
Aclaris Therapeutics
ACRS
$858M
$3.67M 0.35%
3,500,000
+100,000
+3% +$305K
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q4 2023 Portfolio in Review

As of Q4 2023, Bain Capital Life Sciences Investors held 33 positions worth $1.04B, up 17% from $894M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $99M in Q4 2023, closing 6 positions and reducing 3 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $71.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Madrigal Pharmaceuticals worth $75.1M.

  • Bain Capital Life Sciences Investors's largest Q4 2023 buy was Madrigal Pharmaceuticals: 324,619 shares worth $75.1M.
  • Bain Capital Life Sciences Investors added most to Annexon in Q4 2023, an estimated $5.84M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2023 reduction was Pharvaris, cutting an estimated $17.8M.
  • Bain Capital Life Sciences Investors fully exited SpringWorks Therapeutics in Q4 2023, selling an estimated $71.2M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 82% of its $1.04B portfolio in Q4 2023.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 6 in Q4 2023.
  • Bain Capital Life Sciences Investors's portfolio value rose 17% quarter-over-quarter to $1.04B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.